
Keywords: اریتروپویتین نوترکیب انسان (rHuEpo); Dialysis; epoetin alfa; recombinant human erythropoietin (rHuEPO); erythropoiesis-stimulating agent (ESA); dose; EPO titration; hemoglobin; red blood cell transfusion rate; anemia management; practice patterns; hospitalization; Medicare reimbursement; end